Literature DB >> 15243936

Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection.

Hans-Joachim Mollenkopf1, Mischo Kursar, Stefan H E Kaufmann.   

Abstract

We addressed the question of whether protective immunity induced by natural infection with Mycobacterium tuberculosis and that induced by vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) differ in the murine model. We infected mice with M. tuberculosis Erdman, cured them by chemotherapy, and subsequently reinfected them with a low dose of M. tuberculosis H37Rv. The course of tuberculosis was compared with that in mice previously vaccinated with BCG Danish 1331. Protection against postprimary M. tuberculosis infection did not differ significantly between the 2 groups. After challenge infection, numbers of interferon- gamma -positive splenocytes did not differ between mice with primary infection and vaccinated mice. Splenocytes from primary M. tuberculosis-infected mice conferred marginally higher protection than did those from BCG-vaccinated mice. Serum transfer did not protect against reinfection in either group. Our data emphasize that natural infection with M. tuberculosis and vaccination with BCG do not differ in their capacity to induce protective immunity against tuberculosis and support the notions that reinfection contributes to the development of active disease and that any novel vaccine against tuberculosis has to perform better than both vaccination with BCG and immunity evoked by natural infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15243936     DOI: 10.1086/422394

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.

Authors:  Pål Johansen; Antonia Fettelschoss; Beat Amstutz; Petra Selchow; Ying Waeckerle-Men; Peter Keller; Vojo Deretic; Leonhard Held; Thomas M Kündig; Erik C Böttger; Peter Sander
Journal:  Clin Vaccine Immunol       Date:  2011-04-06

2.  BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease.

Authors:  Liana Tsenova; Ryhor Harbacheuski; Nackmoon Sung; Evette Ellison; Dorothy Fallows; Gilla Kaplan
Journal:  Vaccine       Date:  2006-11-27       Impact factor: 3.641

3.  Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis.

Authors:  Hans Joachim Mollenkopf; Leander Grode; Jens Mattow; Maik Stein; Peggy Mann; Bernhard Knapp; Jeffrey Ulmer; Stefan H E Kaufmann
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Cutting Edge: Bacillus Calmette-Guérin-Induced T Cells Shape Mycobacterium tuberculosis Infection before Reducing the Bacterial Burden.

Authors:  Jared L Delahaye; Benjamin H Gern; Sara B Cohen; Courtney R Plumlee; Shahin Shafiani; Michael Y Gerner; Kevin B Urdahl
Journal:  J Immunol       Date:  2019-07-15       Impact factor: 5.422

Review 5.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

6.  Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF.

Authors:  W E Lawson; S W Grant; V Ambrosini; K E Womble; E P Dawson; K B Lane; C Markin; E Renzoni; P Lympany; A Q Thomas; J Roldan; T A Scott; T S Blackwell; J A Phillips; J E Loyd; R M du Bois
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

Review 7.  Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control.

Authors:  Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain.

Authors:  Sarah A Marcus; Howard Steinberg; Adel M Talaat
Journal:  Vaccine       Date:  2015-09-09       Impact factor: 3.641

Review 9.  Novel vaccination strategies against tuberculosis.

Authors:  Peter Andersen; Stefan H E Kaufmann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

10.  Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection.

Authors:  Edward O Ronan; Lian Ni Lee; Peter C L Beverley; Elma Z Tchilian
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.